Cade Komar is a student from Phoenix, Arizona, currently attending Colorado State University where he is pursuing a dual degree in biomedical engineering and mechanical engineering. Cade was born with Severe Hemophilia A and became involved with the…
Explore the SeriesWe asked community members to share their thoughts on the issues that matter most to them. This video series covers research, access to health care, diagnostic difficulties, transitioning to adulthood and more – all from the…
At the turn of the 21st century, there was great excitement and anticipation of gene therapy as a ‘curative’ treatment for hemophilia A and B patients, particularly among those with moderate-to-severe forms of the disease. However, a recent forum…
Explore the latest updates on federal budget reconciliation, healthcare lawsuits, and state-level policy changes impacting bleeding disorders. Learn how NBDF is advocating for access, funding, and patient protections.Federal: …
An analysis of the My Life, Our Future genetic database found that people with severe hemophilia A who are Black or Hispanic had a higher risk of developing inhibitors. It also found that the risk of inhibitor development was…
Mayra Cantu, from Oswego,Il. I am a symptomatic hemophilia A carrier. I have three sons with severe Hemophilia A. The boys keep me on my toes. I have been involved in the bleeding disorders community for 20 years now. I’m looking forward to this new…
Stacy J. Pechter, MS, BSN, RN, is a hematology-oncology nurse and nursing informatics specialist with more than a decade of involvement in the bleeding disorder community. Living with a rare bleeding disorder, they bring both personal insight and…
Concizumab-mtci (Alhemo®) has received approval from the US Food and Drug Administration (FDA) as a once-daily prophylactic treatment for patients aged 12 years and older with hemophilia A or B without inhibitors.This new approval results…